Annual Cash & Cash Equivalents
$3.00 M
-$12.54 M-80.71%
December 31, 2023
Summary
- As of February 7, 2025, SEEL annual cash & cash equivalents is $3.00 million, with the most recent change of -$12.54 million (-80.71%) on December 31, 2023.
- During the last 3 years, SEEL annual cash & cash equivalents has fallen by -$12.67 million (-80.87%).
- SEEL annual cash & cash equivalents is now -96.19% below its all-time high of $78.73 million, reached on December 31, 2021.
Performance
SEEL Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$294.00 K
-$230.00 K-43.89%
June 30, 2024
Summary
- As of February 7, 2025, SEEL quarterly cash and cash equivalents is $294.00 thousand, with the most recent change of -$230.00 thousand (-43.89%) on June 30, 2024.
- Over the past year, SEEL quarterly cash and cash equivalents has dropped by -$2.29 million (-88.62%).
- SEEL quarterly cash and cash equivalents is now -99.66% below its all-time high of $87.20 million, reached on June 30, 2021.
Performance
SEEL Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
SEEL Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -80.7% | -88.6% |
| 3 y3 years | -80.9% | -98.1% |
| 5 y5 years | -16.3% | -97.0% |
SEEL Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -96.2% | at low | -99.6% | at low |
| 5 y | 5-year | -96.2% | at low | -99.7% | at low |
| alltime | all time | -96.2% | +2149.3% | -99.7% | +43.3% |
Seelos Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2024 | - | $294.00 K(-43.9%) |
| Mar 2024 | - | $524.00 K(-82.5%) |
| Dec 2023 | $3.00 M(-80.7%) | $3.00 M(+15.9%) |
| Sep 2023 | - | $2.58 M(-55.8%) |
| Jun 2023 | - | $5.84 M(-58.4%) |
| Mar 2023 | - | $14.06 M(-9.5%) |
| Dec 2022 | $15.53 M(-80.3%) | $15.53 M(-49.1%) |
| Sep 2022 | - | $30.51 M(-26.0%) |
| Jun 2022 | - | $41.25 M(-33.2%) |
| Mar 2022 | - | $61.77 M(-21.5%) |
| Dec 2021 | $78.73 M(+402.7%) | $78.73 M(+2.5%) |
| Sep 2021 | - | $76.83 M(-11.9%) |
| Jun 2021 | - | $87.20 M(+125.4%) |
| Mar 2021 | - | $38.69 M(+147.0%) |
| Dec 2020 | $15.66 M(+52.6%) | $15.66 M(+94.5%) |
| Sep 2020 | - | $8.05 M(+37.6%) |
| Jun 2020 | - | $5.85 M(-53.9%) |
| Mar 2020 | - | $12.69 M(+23.7%) |
| Dec 2019 | $10.26 M(+186.7%) | $10.26 M(-33.0%) |
| Sep 2019 | - | $15.31 M(+57.4%) |
| Jun 2019 | - | $9.73 M(-13.9%) |
| Mar 2019 | - | $11.29 M(+215.5%) |
| Dec 2018 | $3.58 M(-43.5%) | $3.58 M(-32.3%) |
| Sep 2018 | - | $5.28 M(-22.7%) |
| Jun 2018 | - | $6.84 M(+20.4%) |
| Mar 2018 | - | $5.68 M(-10.3%) |
| Dec 2017 | $6.33 M(+203.4%) | $6.33 M(-25.2%) |
| Sep 2017 | - | $8.46 M(+8.2%) |
| Jun 2017 | - | $7.82 M(+107.9%) |
| Mar 2017 | - | $3.76 M(+80.3%) |
| Dec 2016 | $2.09 M(-46.3%) | $2.09 M(-62.8%) |
| Sep 2016 | - | $5.61 M(+106.2%) |
| Jun 2016 | - | $2.72 M(-60.6%) |
| Mar 2016 | - | $6.91 M(+77.7%) |
| Dec 2015 | $3.89 M(-65.9%) | $3.89 M(-33.1%) |
| Sep 2015 | - | $5.81 M(-21.8%) |
| Jun 2015 | - | $7.43 M(-54.0%) |
| Mar 2015 | - | $16.16 M(+41.7%) |
| Dec 2014 | $11.40 M(-46.7%) | $11.40 M(-29.2%) |
| Sep 2014 | - | $16.11 M(-7.5%) |
| Jun 2014 | - | $17.42 M(-22.5%) |
| Mar 2014 | - | $22.49 M(+5.1%) |
| Dec 2013 | $21.41 M(+41.5%) | $21.41 M(+3.8%) |
| Sep 2013 | - | $20.62 M(-16.7%) |
| Jun 2013 | - | $24.76 M(+75.6%) |
| Mar 2013 | - | $14.10 M(-6.8%) |
| Dec 2012 | $15.13 M(+103.5%) | $15.13 M(-10.3%) |
| Sep 2012 | - | $16.86 M(-6.0%) |
| Jun 2012 | - | $17.94 M(-16.7%) |
| Mar 2012 | - | $21.53 M(+189.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2011 | $7.43 M(-18.7%) | $7.43 M(-16.3%) |
| Sep 2011 | - | $8.88 M(-2.9%) |
| Jun 2011 | - | $9.14 M(-10.2%) |
| Mar 2011 | - | $10.18 M(+11.3%) |
| Dec 2010 | $9.15 M(+1805.8%) | $9.15 M(+417.3%) |
| Sep 2010 | - | $1.77 M(-58.1%) |
| Jun 2010 | - | $4.22 M(+65.5%) |
| Mar 2010 | - | $2.55 M(+430.7%) |
| Dec 2009 | $479.90 K(-83.2%) | $479.90 K(-68.8%) |
| Sep 2009 | - | $1.54 M(-45.3%) |
| Jun 2009 | - | $2.81 M(-25.2%) |
| Mar 2009 | - | $3.76 M(+31.3%) |
| Dec 2008 | $2.86 M(+4.6%) | $2.86 M(+99.2%) |
| Sep 2008 | - | $1.44 M(-57.5%) |
| Jun 2008 | - | $3.38 M(+41.9%) |
| Mar 2008 | - | $2.38 M(-12.9%) |
| Dec 2007 | $2.74 M(-75.3%) | $2.74 M(+39.8%) |
| Sep 2007 | - | $1.96 M(-36.5%) |
| Jun 2007 | - | $3.08 M(-62.3%) |
| Mar 2007 | - | $8.16 M(-26.3%) |
| Dec 2006 | $11.07 M(+274.7%) | $11.07 M(+177.1%) |
| Sep 2006 | - | $3.99 M(-14.9%) |
| Jun 2006 | - | $4.69 M(-14.3%) |
| Mar 2006 | - | $5.48 M(+85.4%) |
| Dec 2005 | $2.95 M(-61.9%) | $2.95 M(-48.2%) |
| Sep 2005 | - | $5.70 M(+51.1%) |
| Jun 2005 | - | $3.77 M(+52.5%) |
| Mar 2005 | - | $2.47 M(-68.1%) |
| Dec 2004 | $7.75 M(-26.1%) | $7.75 M(+34.0%) |
| Sep 2004 | - | $5.78 M(-45.6%) |
| Jun 2004 | - | $10.63 M(+100.7%) |
| Mar 2004 | - | $5.30 M(-49.5%) |
| Dec 2003 | $10.48 M(+912.4%) | $10.48 M(+45.5%) |
| Sep 2003 | - | $7.20 M(+365.9%) |
| Jun 2003 | - | $1.55 M(+653.6%) |
| Mar 2003 | - | $205.10 K(-80.2%) |
| Dec 2002 | $1.04 M(-92.0%) | $1.04 M(-78.5%) |
| Sep 2002 | - | $4.81 M(-57.9%) |
| Jun 2002 | - | $11.43 M(+90.3%) |
| Mar 2002 | - | $6.01 M(-53.5%) |
| Dec 2001 | $12.91 M(-53.4%) | $12.91 M(-18.9%) |
| Sep 2001 | - | $15.92 M(-15.1%) |
| Jun 2001 | - | $18.76 M(-18.3%) |
| Mar 2001 | - | $22.97 M(-17.1%) |
| Dec 2000 | $27.70 M(+443.2%) | $27.70 M(-23.6%) |
| Sep 2000 | - | $36.27 M(+152.3%) |
| Jun 2000 | - | $14.37 M(+49.2%) |
| Mar 2000 | - | $9.64 M |
| Dec 1999 | $5.10 M(+3728.8%) | - |
| Dec 1997 | $133.20 K | - |
FAQ
- What is Seelos Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Seelos Therapeutics?
- What is Seelos Therapeutics annual cash & cash equivalents year-on-year change?
- What is Seelos Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Seelos Therapeutics?
- What is Seelos Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Seelos Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of SEEL is $3.00 M
What is the all time high annual cash & cash equivalents for Seelos Therapeutics?
Seelos Therapeutics all-time high annual cash & cash equivalents is $78.73 M
What is Seelos Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, SEEL annual cash & cash equivalents has changed by -$12.54 M (-80.71%)
What is Seelos Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of SEEL is $294.00 K
What is the all time high quarterly cash and cash equivalents for Seelos Therapeutics?
Seelos Therapeutics all-time high quarterly cash and cash equivalents is $87.20 M
What is Seelos Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, SEEL quarterly cash and cash equivalents has changed by -$2.29 M (-88.62%)